Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Editorial: Silent But Detectable-High-Throughput Proteomics to Identify Clinically Significant Liver Disease.
Journal: Alimentary pharmacology & therapeutics
Published: May 05, 2026
Editorial: Refining the Natural History of MASLD by Imaging-Based Markers: The GOLDMINE Study. Authors' Reply.
Journal: Alimentary pharmacology & therapeutics
Published: May 05, 2026
Progressive Multifocal Leukoencephalopathy: A Rare Cause of Altered Mentation.
Journal: Cureus
Published: March 02, 2026
Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes.
Journal: Alimentary pharmacology & therapeutics
Published: February 02, 2026
Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid-Lowering.
Journal: Alimentary pharmacology & therapeutics
Published: January 16, 2026
Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.
Journal: Gastroenterology
Published: October 08, 2025
Neither Metabolic Dysfunction Associated Steatotic Liver Disease Presence Nor Fibrosis Severity, By FIB4, Predicts Adverse Pregnancy Outcomes.
Journal: Journal of clinical gastroenterology
Published: July 06, 2025
Pregnancy does not affect liver chemistries in metabolic dysfunction-associated steatotic liver disease.
Journal: Hepatology communications
Published: June 30, 2024
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.
Journal: The American journal of gastroenterology
Published: March 22, 2024
Reply: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Journal: Hepatology (Baltimore, Md.)
Published: February 21, 2024
Editorial: Assessing advanced fibrosis in metabolic-associated steatotic liver disease-The MAFLD fibrosis score.
Journal: Alimentary pharmacology & therapeutics
Published: November 21, 2023
Editorial: first-degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis-authors' reply.
Journal: Alimentary pharmacology & therapeutics
Published: April 13, 2023
Last Updated: 09/26/2026